- Home
- QURE vs LIMN Comparison
QURE vs LIMN Comparison
Compare QURE & LIMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- LIMN
- Stock Information
- Founded
- QURE 1998
- LIMN 2018
- Country
- QURE Netherlands
- LIMN United States
- Employees
- QURE N/A
- LIMN N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- LIMN
- Sector
- QURE Health Care
- LIMN
- Exchange
- QURE Nasdaq
- LIMN NYSE
- Market Cap
- QURE 725.4M
- LIMN 623.8M
- IPO Year
- QURE 2007
- LIMN N/A
- Fundamental
- Price
- QURE $14.24
- LIMN $16.60
- Analyst Decision
- QURE Strong Buy
- LIMN
- Analyst Count
- QURE 10
- LIMN 0
- Target Price
- QURE $37.20
- LIMN N/A
- AVG Volume (30 Days)
- QURE 1.3M
- LIMN 665.9K
- Earning Date
- QURE 07-31-2025
- LIMN 01-01-0001
- Dividend Yield
- QURE N/A
- LIMN N/A
- EPS Growth
- QURE N/A
- LIMN N/A
- EPS
- QURE N/A
- LIMN N/A
- Revenue
- QURE $20,201,000.00
- LIMN N/A
- Revenue This Year
- QURE N/A
- LIMN N/A
- Revenue Next Year
- QURE $278.91
- LIMN N/A
- P/E Ratio
- QURE N/A
- LIMN N/A
- Revenue Growth
- QURE 6.30
- LIMN N/A
- 52 Week Low
- QURE $3.73
- LIMN $4.40
- 52 Week High
- QURE $19.18
- LIMN $33.66
- Technical
- Relative Strength Index (RSI)
- QURE 45.40
- LIMN N/A
- Support Level
- QURE $13.65
- LIMN N/A
- Resistance Level
- QURE $15.35
- LIMN N/A
- Average True Range (ATR)
- QURE 0.90
- LIMN 0.00
- MACD
- QURE -0.28
- LIMN 0.00
- Stochastic Oscillator
- QURE 14.68
- LIMN 0.00
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About LIMN LIMINATUS PHARMA INC
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.